| Number of visits (%) or median [IQR] | Nb. of patients | Coefficient (95% CI) | p-value |
---|---|---|---|---|
Buprenorphine (ref) | 640 (60.6) | 154 | Â | Â |
Methadone | 416 (39.4) | 111 | 0.00 (-0.41; 0.37) | 0.98 |
Female gender | 286 (27.1) | 72 | 0.16 (-0.09; 0.39) | 0.20 |
Agea | 36 [32-39] | Â | -0.69 (-0.96; -0.43) | < 10 -3 |
Owner or renter of their house | 757 (71.7) | 189 | -0.24 (-0.45; 0.00) | 0.03 |
Good housing conditionsb | 868 (82.4) | 210 | -0.13 (-0.39; 0.08) | 0.22 |
Heavy drinkingc | 213 (20.4) | 95 | 0.15 (-0.07; 0.40) | 0.20 |
Cocaine used | 277 (26.3) | 115 | 0.91 (0.67; 1.20) | < 10 -3 |
Cannabis use (daily)d | 467 (44.4) | 156 | 0.45 (0.29; 0.62) | < 10 -3 |
Benzodiazepine consumptiond | 358 (33.9) | 150 | 0.62 (0.44; 0.81) | < 10 -3 |
HIV clinical stage | Â | Â | Â | Â |
A (ref) | 474 (44.9) | 138 | Â | Â |
B | 518 (49.1) | 125 | -0.24 (-0.49; -0.01) | 0.06 |
C | 63 (6.0) | 22 | -0.68 (-1.17; -0.28) | 0.003 |
Depressive symptomse | 666 (63.2) | 200 | 0.34 (0.18; 0.52) | < 10 -3 |
Withdrawal symptoms | 204 (19.3) | 122 | 0.81 (0.56; 1.07) | < 10 -3 |
Time since first injection (years)a | 16 [13-20] | Â | -0.56 (-0.86; -0.32) | < 10 -3 |
Time since first positive HIV test (years)a | 11 [8-13] | Â | -1.00 (-1.35; -0.76) | < 10 -3 |
Time since OMT initiation (months)f | 16 [7-30] | Â | -0.29 (-0.39; -0.22) | < 10 -3 |
Undetectable viral charge | 366 (34.9) | 124 | -0.25 (-0.46; -0.03) | 0.03 |
CD4 cell count/mm3 < 200 | 57 (5.5) | 32 | -0.26 (-0.65; 0.15) | 0.20 |
Receiving ART | 395 (37.4) | 119 | -0.52 (-0.70; -0.30) | < 10 -3 |
Complete trust in physicians | 824 (78.4) | 196 | -0.33 (-0.62; 0.10) | 0.01 |
Low prescribed dose of OMTg | 676 (66.8) | 169 | -0.22 (-0.43;0.04) | 0.06 |